Market revenue in 2023 | USD 3,321.7 million |
Market revenue in 2030 | USD 4,371.3 million |
Growth rate | 4% (CAGR from 2023 to 2030) |
Largest segment | Subunit vaccines |
Fastest growing segment | Subunit Vaccines |
Historical data | 2018 - 2022 |
Base year | 2023 |
Forecast period | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Subunit Vaccines, Inactivated, Live Attenuated, MRNA vaccines, Viral vector vaccines |
Key market players worldwide | Serum Institute of India Pvt. Ltd., CSL Ltd, Sanofi SA, GSK PLC, Merck & Co Inc, Pfizer Inc, Sinovac Biotech Ltd, BioNTech SE ADR, AstraZeneca PLC, Moderna Inc |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to vaccine market will help companies and investors design strategic landscapes.
Subunit vaccines was the largest segment with a revenue share of 34.12% in 2023. Horizon Databook has segmented the UK vaccine market based on subunit vaccines, inactivated, live attenuated, mrna vaccines, viral vector vaccines covering the revenue growth of each sub-segment from 2018 to 2030.
The vaccine market in the UK is one of the major markets in the region. High vaccine uptake against the flu, better immunization programs, favorable government initiatives, and increased R&D activities in the country are driving the market growth. In addition, the high disease burden and significant government interventions in vaccination programs are some of the factors driving the market.
For instance, in September 2018, Public Health England announced new flu vaccination recommendations for individuals aged more than 65. The authority recommended the adjuvanted trivalent influenza vaccine to people with higher influenza risk.
Moreover, ongoing collaborations between leading participants and governments to maintain a robust vaccine supply are propelling market growth. For instance, in December 2022, Moderna announced its plans to invest in mRNA R&D in the UK and establish a new vaccine development center with a capacity to manufacture up to 250 million vaccines a year.
Horizon Databook provides a detailed overview of country-level data and insights on the UK vaccine market , including forecasts for subscribers. This country databook contains high-level insights into UK vaccine market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
No related regions found.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account